These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15613931)

  • 1. An open-label pilot study of levetiracetam for essential tremor.
    Ondo WG; Jimenez JE; Vuong KD; Jankovic J
    Clin Neuropharmacol; 2004; 27(6):274-7. PubMed ID: 15613931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor.
    Handforth A; Martin FC
    Mov Disord; 2004 Oct; 19(10):1215-21. PubMed ID: 15390011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levetiracetam is not effective for essential tremor.
    Elble RJ; Lyons KE; Pahwa R
    Clin Neuropharmacol; 2007; 30(6):350-6. PubMed ID: 18090460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study.
    Striano P; Coppola A; Vacca G; Zara F; Brescia Morra V; Orefice G; Striano S
    J Neurol; 2006 Jun; 253(6):762-6. PubMed ID: 16683063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness and safety of levetiracetam in patients with essential tremor: data from an open 11-week follow-up trial].
    Sanz-Cartagena P; Fossas P; Floriach-Robert M; Serra-Prat M; Cano A; Palomeras E
    Rev Neurol; 2007 Aug 1-15; 45(3):134-6. PubMed ID: 17661270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia.
    Jorns TP; Johnston A; Zakrzewska JM
    Eur J Neurol; 2009 Jun; 16(6):740-4. PubMed ID: 19475723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levetiracetam for the treatment of essential tremor.
    Sullivan KL; Hauser RA; Zesiewicz TA
    Mov Disord; 2005 May; 20(5):640. PubMed ID: 15756652
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of levetiracetam on essential tremor.
    Bushara KO; Malik T; Exconde RE
    Neurology; 2005 Mar; 64(6):1078-80. PubMed ID: 15781835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zonisamide for essential tremor.
    Ondo WG
    Clin Neuropharmacol; 2007; 30(6):345-9. PubMed ID: 18090459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.
    Ferrendelli JA; French J; Leppik I; Morrell MJ; Herbeuval A; Han J; Magnus L
    Epilepsy Behav; 2003 Dec; 4(6):702-9. PubMed ID: 14698704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study of levetiracetam for the treatment of social anxiety disorder.
    Simon NM; Worthington JJ; Doyle AC; Hoge EA; Kinrys G; Fischmann D; Link N; Pollack MH
    J Clin Psychiatry; 2004 Sep; 65(9):1219-22. PubMed ID: 15367048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study.
    Morrell MJ; Leppik I; French J; Ferrendelli J; Han J; Magnus L
    Epilepsy Res; 2003 May; 54(2-3):153-61. PubMed ID: 12837566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study.
    Papp LA
    J Clin Psychiatry; 2006 Oct; 67(10):1573-6. PubMed ID: 17107249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective pilot study of levetiracetam for body dysmorphic disorder.
    Phillips KA; Menard W
    CNS Spectr; 2009 May; 14(5):252-60. PubMed ID: 19407724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis.
    Feys P; D'hooghe MB; Nagels G; Helsen WF
    Mult Scler; 2009 Mar; 15(3):371-8. PubMed ID: 19168602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levetiracetam for treatment-refractory posttraumatic stress disorder.
    Kinrys G; Wygant LE; Pardo TB; Melo M
    J Clin Psychiatry; 2006 Feb; 67(2):211-4. PubMed ID: 16566615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus.
    Frucht SJ; Louis ED; Chuang C; Fahn S
    Neurology; 2001 Sep; 57(6):1112-4. PubMed ID: 11571347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levetiracetam for treatment of premenstrual dysphoric disorder: a pilot, open-label study.
    Kayatekin ZE; Sabo AN; Halbreich U
    Arch Womens Ment Health; 2008 Jul; 11(3):207-11. PubMed ID: 18493713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.